Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Stock Short Interest Report for October

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a significant growth in short interest during the month of October. As of October 15th, there was short interest totaling 31,307 shares, a growth of 76.0% from the September 30th total of 17,790 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average daily volume of 54,073 shares, the days-to-cover ratio is presently 0.6 days.

Shuttle Pharmaceuticals Trading Down 1.5%

Shares of NASDAQ SHPH traded down $0.08 during midday trading on Friday, hitting $5.15. The company’s stock had a trading volume of 20,479 shares, compared to its average volume of 43,890. The stock has a fifty day moving average price of $4.18 and a 200 day moving average price of $7.13. The firm has a market capitalization of $24.51 million, a price-to-earnings ratio of -0.28 and a beta of 0.11. Shuttle Pharmaceuticals has a one year low of $2.58 and a one year high of $44.40.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, July 4th. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 14th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has an average rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc (NASDAQ:SHPH) is a clinical-stage biopharmaceutical company focused on developing therapies designed to improve the effectiveness of radiation treatment for cancer. The company’s research is centered on radiosensitizers, drugs intended to make cancer cells more vulnerable to radiation while potentially limiting damage to surrounding healthy tissue.

Shuttle’s lead candidate is ropidoxuridine, also known as iododeoxyuridine or IUdR, an investigational radiosensitizing agent being evaluated for use with radiotherapy.